Home › Trial NCT03740893
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
- Trial IDNCT03740893
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorInstitute of Cancer Research, United Kingdom
- Enrollment119
- Start date2019-10-15
- ConditionsBreast Neoplasm · Triple Negative Breast Cancer (TNBC) · HRD
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.